
Results of a phase 4, open-label, multicenter study indicate that low-dose acitretin (Soriatane, Connetics) in moderate to severe psoriasis patients provides efficacy as monotherapy by 24 weeks, but requires patience, said Gerald G. Krueger, M.D., at the American Academy of Dermatology's Academy '06.
